MOTS-c
Reviews describe MOTS-c as a peptide encoded in mitochondrial DNA rather than the cell nucleus, and report activation of the energy-sensing enzyme AMPK and regulation of the folate–methionine cycle in laboratory models.
Full reference page →
Research area
Weight & Metabolism Research
Studies the peptide signals that regulate glucose handling, appetite, and energy expenditure — incretin biology, mitochondrial signalling, and the enzymes of the NAD+ pathway.
- Compound classes
- 3Compound classes
- Randomised human trials
- 4Randomised human trials
- Field references
- 12Field references
- Last retrieved
- 2026-08-03Last retrieved
Read at your level
The standard reading.
Metabolic research asks how the body decides what to do with energy — whether to store it, burn it, or ask for more. Much of that decision-making is carried out by peptide signals travelling between the gut, the pancreas, fat tissue, and the hypothalamus (a control centre in the brain), which is why the field sits so heavily in peptide science.
The best understood of these are the incretins: hormones the intestine releases after a meal that amplify insulin release, but only when blood glucose is already high. Their discovery solved a long-standing puzzle — that glucose swallowed by mouth triggers a far larger insulin response than the same amount put straight into a vein — and the reviews describing that mechanism are among the most cited in modern endocrinology.
Significance
Why this area is studied
This is the area of peptide science with the strongest human evidence by a wide margin, and it is worth understanding why. Incretin biology was worked out in humans first, over decades, before anyone engineered a molecule from it. That order — establish the mechanism, then build molecules to use it — is the exception in peptide science rather than the rule, and it is why metabolic trial counts look so different from those in neighbouring fields.
Mechanism
The science, in plain terms
Glucose-dependent insulin release
Incretin receptors on the beta cells of the pancreas amplify insulin release only when blood glucose is already high. That dependency is the mechanistically interesting part: the signal gives permission for insulin to be released rather than ordering it directly, which is why it behaves differently from insulin itself.
Gastric emptying and satiety
The same hormones slow how fast the stomach empties and act on circuits in the hypothalamus that register fullness. Reviews of gut hormones and appetite regulation describe these as two parallel effects of one signal rather than separate mechanisms.
Cellular energy sensing
Beneath the hormonal layer sits AMPK, an enzyme that reads the balance of AMP to ATP — the cell’s low-fuel and full-fuel markers — and switches metabolism between building up and breaking down. It is the cell-level counterpart to the whole-body signals above, and several mitochondrial-derived peptides are studied for their effect on it.
Practice
How the research is conducted
The study designs that generate evidence in this area. Each carries its own interpretive limits — which is why the evidence hierarchy is worth reading alongside them.
- 01
Glucose tolerance and clamp studies measuring insulin response under controlled conditions
- 02
Rodent models of diet-induced obesity and insulin resistance
- 03
Cell-based tests of receptor binding, selectivity, and the signalling that follows
- 04
Body-composition imaging to separate fat mass from lean mass in intervention studies
Open questions
What researchers are still testing
These are questions under investigation, not expected outcomes. Listing them is a description of where the field’s attention currently sits — not a suggestion that any of them will resolve favourably.
- 01
Whether mitochondrial-derived peptides such as MOTS-c do anything measurable when given to humans from outside the body, which has not been tested in a controlled trial
- 02
How much of the metabolic effect of energy-sensing pathways can be triggered with a drug without disrupting the body’s normal regulation
- 03
Whether enzyme inhibitors that shift the cell’s methylation balance carry over from rodent obesity models into human physiology at all
Constraints
Limitations worth holding onto
The strength of the incretin evidence does not transfer to the rest of this area. Compounds studied for mitochondrial or enzymatic mechanisms sit almost entirely in cell and animal work, and several have no indexed human trials whatsoever.
Metabolic outcomes are also unusually easy to misread. A change in weight is a mix of fat, lean tissue, and fluid, so a study that reports only total mass has not told you which of those actually changed.
Index
Compound classes in this area
AOD9604
The literature describes a synthetic fragment from the tail end (C-terminus) of human growth hormone, investigated on the hypothesis that its fat-breakdown (lipolytic) activity could be separated from its growth-promoting activity.
Full reference page →
NNMT inhibitors (5-Amino-1MQ)
Published reviews describe inhibition of the enzyme nicotinamide N-methyltransferase (NNMT) and its role in cellular metabolism. Note that the indexed literature treats this as a small molecule, not a peptide.
Full reference page →
Sources
References for this field
Review articles covering the area as a whole, retrieved from PubMed. The explanatory sections above summarise what work of this kind reports.
This is a bibliographic and educational resource for research professionals. It is not medical, clinical, or legal advice, and nothing here is a recommendation to use any compound. Peptide research is an evolving field: what the literature contains changes as new work is published. Readers are responsible for evaluating the primary sources themselves and for consulting qualified professionals in their own jurisdiction.